MyDrHank vs REMEVi

Strengths

• +Prices are published openly on the product pages, before any intake quiz — most compounded competitors gate the number behind a questionnaire
• +A real oral semaglutide tablet ($249/mo month-to-month) beside the weekly injection, so the needle is optional on the semaglutide line
• +The GLP-1 pages state the price stays the same at every dose, so titrating up does not raise the monthly cost
• +Six prescription lines on one account — weight loss, longevity, peptides and NAD+, sexual health, hair growth and strength — with free shipping included
• +Clean against the FDA warning-letter database: no letter on file under the brand, the entity or the domain

Where it loses points

• –Every price MyDrHank displays is the twelve-month prepay rung — its price component renders the cheapest term in the ladder, so the month-to-month rate ($259 semaglutide, $349 tirzepatide) appears on no page on the site
• –Month-to-month, it is expensive: $259 semaglutide against a $179 median across the providers here that disclose one, and $349 tirzepatide against a $249 median
• –One advertised price is purchasable at no tier — a footnote quotes "$200/mo for compounded tirzepatide" when the cheapest tirzepatide rung is $240, and the "$171/mo" beside it is the oral product's yearly rate, not injectable semaglutide's ($178)
• –An FAQ describes a twelve-month prepay rate as a plan with "no contract"
• –Compounded only and not FDA-approved — no brand Wegovy, Ozempic, Zepbound or Mounjaro lane at any price
• –The operating entity is named — Dr. Hank, LLC, credited in the privacy policy and terms of use — but nobody clinical is: no medical director or prescriber appears anywhere, no lab or monitoring program is published, and the compounding pharmacy is described only as "an FDA-registered U.S. pharmacy"
• –The trust row reads "HIPAA-aware", not HIPAA-compliant — a hedge worth noticing on a site handling prescription intake
• –No served-states list appears on the consumer site; the affiliate terms exclude Kansas, Louisiana, Mississippi, New Mexico, North Dakota and West Virginia

Strengths

• +A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
• +Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
• +A daily oral semaglutide tablet is offered alongside the injection
• +Available in all 50 states and DC, with no minimum commitment and no cancellation fee

Where it loses points

• –The flat rate is the highest entry price of the top-scoring programs here; the cheaper $149 figure needs a full year
• –No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
• –Compounded semaglutide and tirzepatide are not FDA-approved finished products